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The relationship between neonatal vitamin K received by the intramuscular (i.m.) route and the development of leukaemia or other
cancers was investigated as part of a national case–control study of childhood cancer, using data abstracted from obstetric and
neonatal records. The analyses included 2530 children diagnosed with cancer before 15 years of age, 1174 of whom had leukaemia
and 4487 control children without cancer. Overall, 39% of cases and 42% of controls had records of i.m. vitamin K administration,
while 24% of cases and 22% of controls had no record of whether or not they had received vitamin K. Using subjects who received
i.m. vitamin K as the baseline group, our analyses found no association between the administration of i.m. vitamin K and either
leukaemia or other cancers as a group. We conclude that there is no convincing evidence that neonatal vitamin K administration,
irrespective of the route by which it is given, influences the risk of children developing leukaemia or any other cancer.
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Vitamin K given by the intramuscular (i.m.) route is known to be
effective in preventing both early haemorrhagic disease in
neonates and late-onset bleeding in older babies (Dam et al,
1952; McNinch and Tripp, 1991; Zipursky, 1999). The efficacy of
oral vitamin K is less certain as there is a recognised problem of
absorption in some babies, and additional difficulties in com-
pliance with multiple-dose oral regimens (Zipursky, 1999; Wariyar
et al, 2000; von Kries et al, 2003).
Concerns about the administration of i.m. vitamin K were raised
by Golding et al (1992) in their report associating i.m., but not
oral, vitamin K with childhood leukaemia. Since then, most
research has failed to find any statistically significant associations
(Ekelund et al, 1993; Klebanoff et al, 1993; Olsen et al, 1994; Ansell
et al, 1996; von Kries et al, 1996; Roman et al, 1997; McKinney et al,
1998; Passmore et al, 1998a, b), although Parker et al (1998) argued
that i.m. vitamin K increases the risk of acute lymphoblastic
leukaemia (ALL) diagnosed between 12 and 71 months of age.
However, a recently published pooled analysis of data from the six
major case–control studies concluded that there was ‘no convin-
cing evidence that i.m. vitamin K is associated with childhood
leukaemia’, including ALL diagnosed between 12 and 71 months of
age (Roman et al, 2002). Given the concerns associated with the
administration of i.m. vitamin K, a wide variety of policies now
operate throughout the United Kingdom (McNinch, 1997;
Zipursky, 1999; Ansell et al, 2001).
The findings for neonatal vitamin K prophylaxis, assembled
during the course of the large multicentre United Kingdom
Childhood Cancer Study (UKCCS), are the focus of this report (UK
Childhood Cancer Study Investigators, 2000).
DATA AND METHODS
Subjects
The United Kingdom Childhood Cancer Study (UKCCS) is a
national population-based case– control study, full details of which
are described elsewhere (UK Childhood Cancer Study Investiga-
tors, 2000). Briefly, children aged 0 –14 years resident in the UK
and diagnosed with pathologically confirmed malignancy between
1992 and 1996 were eligible for inclusion. For each case, two
controls matched on sex, month and year of birth, and region of
residence at diagnosis were randomly selected and recruited from
population registers held by the (former) Family Health Service
Authorities. At the time of the interview, parents were asked for
consent to abstract their own and their child’s medical records,
including neonatal and obstetric notes. Information was system-
atically abstracted from obstetric and neonatal records by specially
trained abstractors onto a previously validated, structured form
designed to be applicable across hospitals and time periods. Data
were abstracted on a wide variety of obstetric and neonatal events,
including whether or not vitamin K was given and, if given, by
which route.
Analyses were confined to England and North Wales, as data
were not collected in South Wales and findings for Scotland have
been previously published (McKinney et al, 1998, 1999).
Of the 2692 cases and 4864 controls available for analyses, 162
cases (6%) and 377 controls (8%) were excluded –56 case children
diagnosed under 3 months of age; 35 children with Down’sReceived 26 March 2003; revised 18 July 2003; accepted 21 July 2003
*Correspondence: Professor E Roman; E-mail: e.roman@leeds.ac.uk
See Appendix for Regional Investigators and Management Committee.
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syndrome; 168 who were the product of multiple pregnancies; and
280 who did not have a corresponding matched case or control
(the majority were controls whose pseudodiagnosis age was less
than 3 months–because their corresponding case was diagnosed
under 3 months of age). After making these exclusions, 2530 cases
and 4487 controls remained, 93% of the subjects whose obstetric
notes were abstracted (Table 1). Analyses were carried out for all
cancers combined (2530 cases), and separately for all leukaemias
combined (1174 cases), acute lymphoblastic leukaemia (ALL, 1001
cases) and all other cancers except leukaemia (1356 cases).
The odds ratios (ORs), 95% confidence intervals (CIs) and two-
sided P-values were estimated using unconditional logistic
regression (Breslow and Day, 1980) with adjustment for the region
of residence at diagnosis (eight in total), sex and age at diagnosis
(in single years). To maximise the robustness of the analyses, the
total pool of controls was the comparator for each diagnostic
group, an approach adopted in other UKCCS analyses (e.g. Beral
et al, 2001). Statistical analyses were conducted using STATA
(version 7.0) (StataCorp, 2001).
RESULTS
Table 2 shows the distribution of cases and controls, associated
ORs and 95% CIs by vitamin K status. Overall, 39% of cases and
42% of controls were recorded as having received i.m. vitamin K
shortly after birth, with 18% of both cases and controls recorded as
having received vitamin K without the route being recorded, and
24% of cases and 22% of controls having no information on
whether vitamin K was given (or not given) written in their notes.
There are no notable differences in the distribution of vitamin K
status by case–control status.
Using the large group of subjects known to have received i.m.
vitamin K as the baseline, no statistically significantly increased
risks for leukaemia are apparent (Table 2). For all cancers
combined, however, the OR was 1.15 (95% CI¼ 1.01–1.31) when
no written record of administration was found, and for cancers
other than leukaemia the OR was 1.39 (1.03–1.90), when vitamin K
was recorded as not given. Children diagnosed with leukaemia
aged between 12 and 71 months were no more or less likely to have
received i.m. vitamin K than children who were not diagnosed with
cancer (Table 3). The proportion of subjects with no recorded
information is, however, generally higher in Table 2 (24% of cases
and 22% of controls) than in Table 3 (19% of cases and 16% of
controls). This reflects the fact that the children included in the
latter table were, on an average, born more recently (data not
shown)–hospital recording practices have improved over time and
babies are now also more likely to receive vitamin K, particularly
by the oral route (Figure 1).
All analyses were repeated with adjustment for low birth weight
(o2501 g, X2501 g), mode of delivery (normal vaginal, caesarean
section, other), admission to special care baby unit
(noþ unknown, yes) and year of birth, but the findings were
unchanged (data not shown).
DISCUSSION
Our analyses, based on neonatal and obstetric records collected
from maternity units across England during the course of a large
population-based case–control study (UK Childhood Cancer
Study Investigators, 2000), found no evidence of an association
between i.m. vitamin K and childhood cancer in general, or
leukaemia in particular. With 2530 cases of cancer–over a
Table 1 Subjects excluded from the analysis by reason for exclusion and
characteristics of those included
Cases Controls
Total available 2692 (100%) 4864 (100%)
Excluded (%) 162 (6%)a 377 (8%)
Diagnosed under
3 months of age
56 —
Down’s syndrome 32 3
Multiple birth 60 108
Unmatchedb 14 266
Included (%) 2530 (94%) 4487 (92%)
Total included 2530 (100%) 4487 (100%)
Sex (%)
Males 1413 (56%) 2487 (55%)
Females 1117 (44%) 2000 (45%)
Age at diagnosis (%)
o1 year 189 (7%) 351 (8%)
1 year 254 (10%) 473 (11%)
2–5 years 1069 (42%) 1926 (43%)
6+ years 1018 (40%) 1737 (39%)
aThree cases diagnosed under 3 months of age also had Down’s syndrome, and two
cases with Down’s syndrome were also part of a multiple birth. bCases or controls
who did not have a corresponding matched case or control after the exclusions had
been made.
Table 2 Distribution of cases and controls, associated odds ratios (OR) and 95% confidence intervals (CI) by vitamin K status
Leukaemia
Vitamin K status All cancers (n¼ 2530) Total (n¼ 1174) ALLa (n¼ 1001) Other cancersb (n¼ 1356) Controls (n¼ 4487)
Number (%)
Intramuscular 991 (39%) 456 (39%) 394 (39%) 535 (39%) 1868 (42%)
Oral 376 (15%) 181 (15%) 154 (15%) 195 (14%) 663 (15%)
Given but route unknown 455 (18%) 233 (20%) 199 (20%) 222 (16%) 815 (18%)
Not given 106 (4%) 39 (3%) 30 (3%) 67 (5%) 162 (4%)
No record 602 (24%) 265 (23%) 224 (22%) 337 (25%) 979 (22%)
OR (95% CI)c
Intramuscular 1.0 1.0 1.0 1.0 —
Oral 1.09 (0.94–1.27) 1.13 (0.92–1.38) 1.11 (0.90–1.38) 1.06 (0.87–1.29) —
Given but route unknown 1.05 (0.91–1.22) 1.19 (0.99–1.43) 1.16 (0.95–1.41) 0.95 (0.79–1.14) —
Not given 1.24 (0.95–1.61) 1.07 (0.74–1.55) 0.98 (0.65–1.49) 1.39 (1.03–1.90)* —
No record 1.15 (1.01–1.31)* 1.18 (0.99–1.41) 1.19 (0.99–1.44) 1.12 (0.95–1.32) —
aALL¼Acute lymphoblastic leukaemia. bCancers other than leukaemia. cCalculated using logistic regression with adjustment for age at diagnosis (single years), sex and region of
residence. *Po0.05.
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thousand of which were leukaemias–and 4487 controls, this is the
most comprehensive study of its kind to have been reported on
this topic.
Although previous investigators tended to follow Golding et al’s
(1992) example and compared children with a written or imputed
record of having received i.m. vitamin K with those who received it
orally or not at all, we have not done so. Our design and large
numbers permitted a comparison between five groups, those with:
1. a written record of having received vitamin K by the i.m. route,
2. a written record of having received vitamin K orally,
3. a written record of having received vitamin K, but by an
unknown route,
4. a written record stating that they had not received vitamin K,
5. no written information (given or not given) regarding vitamin
K administration.
Overall, 39% of cases and 42% of controls had a written record
of i.m. vitamin K administration, while 24% of cases and 22% of
controls had no record of whether or not they had received vitamin
K. Using subjects who received i.m. vitamin K as the baseline, no
association between i.m. vitamin K and either leukaemia or any
other cancer was found. For cancers other than leukaemia,
however, the OR was 1.39 (95% CI¼ 1.03–1.90) when vitamin K
was recorded as not given and for all cancers combined it was 1.15
(1.01–1.31), when no written record of administration was found.
The increase in cancer risk associated with having no written
vitamin K record became more pronounced when the analysis was
restricted to children diagnosed between 12 and 71 months of age:
the ORs for all cancers, ALL and cancers other than leukaemia
being 1.28(1.06– 1.56), 1.28(1.00– 1.64) and 1.27(0.98 –1.65), re-
spectively. The generalised nature of this effect, coupled with the
fact that cases born in smaller maternity units were more likely
than cases born in larger units to have no written record of
administration (data not shown), suggests that either chance or
bias could have had a role to play in this result.
The lack of an association reported here between childhood
leukaemia and the i.m. administration of vitamin K accords with
the majority of individual studies to have reported on this topic
(Ekelund et al, 1993; Klebanoff et al, 1993; Olsen et al, 1994; Ansell
et al, 1996; von Kries et al, 1996; Roman et al, 1997; McKinney et al,
1998; Passmore et al, 1998a, b) and with the results of an individual
record-based pooled analysis of the six major case– control studies
(Roman et al, 2002). The one exception is a study carried out in the
former Northern Health region of England which, although it
found no association for all childhood ALL (OR¼ 1.20, 95%
CI¼ 0.75–1.92, based on 207 cases), reported a statistically
significantly raised OR for ALL diagnosed between 12 and 71
months of age (OR¼ 1.79, 95% CI¼ 1.02–3.15, based on 144
cases) (Parker et al, 1998). To investigate this further, a meta-
analysis of the results published by Roman et al (2002) and the
results reported here has been undertaken. In order to do this, the
analyses reported here were repeated comparing oralþ given
unknown routeþ not givenþ no record (baseline group) with i.m.
vitamin K. No associations were observed between i.m. vitamin K
and any diagnostic group, with the pooled OR for ALL diagnosed
between 12 and 71 months being: OR¼ 0.98, 95% CI¼ 0.79–1.22
(based on 1201 cases). In light of all the available evidence, the
most likely explanation for the finding of Parker et al (1998) would
seem to be chance.
Accordingly, we conclude that there is no convincing evidence
that neonatal vitamin K administration, irrespective of the route by
which it is given, influences the risk of children developing
leukaemia or any other cancer.
Table 3 Distribution of cases and controls, associated odds ratios (OR) and 95% confidence intervals (CI) by vitamin K status for subjects aged 12–71
months
Leukaemia
Vitamin K status All cancers Total ALLa Other cancersb Controls
Number (%)
Intramuscular 531 (40%) 294 (40%) 265 (40%) 237 (40%) 1037 (43%)
Oral 238 (18%) 135 (18%) 119 (18%) 103 (17%) 444 (19%)
Given but route unknown 266 (20%) 148 (20%) 134 (20%) 118 (16%) 461 (18%)
Not given 39 (3%) 15 (2%) 12 (2%) 24 (4%) 74 (3%)
No record 249 (19%) 140 (19%) 125 (19%) 109 (18%) 383 (16%)
OR (95% CI)c
Intramuscular 1.0 1.0 1.0 1.0 —
Oral 1.06 (0.88–1.29) 1.16 (0.88–1.42) 1.10 (0.86–1.41) 1.01 (0.78–1.32) —
Given but route unknown 1.13 (0.93–1.36) 1.12 (0.89–1.42) 1.13 (0.88–1.44) 1.14 (0.88–1.47) —
Not given 1.04 (0.69–1.56) 0.73 (0.41–1.30) 0.66 (0.35–1.24) 1.43 (0.87–2.32) —
No record 1.28 (1.06–1.56)* 1.29 (1.02–1.64)* 1.28 (1.00–1.64)* 1.27 (0.98–1.65) —
aALL¼Acute lymphoblastic leukaemia. bCancers other than leukaemia. cCalculated using logistic regression with adjustment for age at diagnosis (single years), sex and region of
residence. *Po0.05.
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Figure 1 Recording of vitamin K administration by year birth.
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